Skip to content
Inciteful Med

Living with Dermatomyositis: Care Team, Monitoring, and Survivorship

Last updated:

Living with dermatomyositis requires a coordinated care team led by a rheumatologist. Strict daily UV protection is medically necessary to prevent systemic flares. Even in remission, routine monitoring of lung function, muscle enzymes, and cancer risk is crucial for long-term health.

Key Takeaways

  • • A multidisciplinary care team for dermatomyositis typically includes a rheumatologist, dermatologist, pulmonologist, and physical therapist.
  • • Strict UV protection is a medical necessity, as UV light can trigger a systemic flare of both skin and muscle symptoms.
  • • Routine blood work, lung function tests, and cancer screenings are required even during remission to ensure the disease remains controlled.
  • • Muscle enzymes can sometimes remain normal during an active disease flare, making it important to track physical symptoms alongside lab results.
  • • Experiencing scanxiety before medical tests is normal, and patients can reduce stress by scheduling a specific time to discuss results with their doctor.

Managing dermatomyositis (DM) is a lifelong commitment that extends far beyond taking medication. Because the disease can affect multiple systems—from your skin and muscles to your lungs and internal organs—success depends on a coordinated team and a “sun-safe” lifestyle [1][2].

Building Your Care Team

Think of your medical team as an orchestra, where each specialist plays a vital role. While your rheumatologist often acts as the “quarterback” or lead coordinator, you will likely need the following experts [2][3]:

  • Dermatologist: Essential for managing stubborn skin rashes and monitoring for skin changes that might signal a flare [4].
  • Pulmonologist: Critical for monitoring lung health. They use Pulmonary Function Tests (PFTs) and imaging to ensure any lung inflammation (ILD) is caught and treated early [2][3].
  • Physical and Occupational Therapists: These specialists help you regain strength safely through tailored exercise programs, which are proven to improve inflammation and prevent muscle scarring [5][6].
  • Oncologist: If your DM is related to an underlying malignancy (paraneoplastic), an oncologist will work closely with your rheumatologist to balance cancer treatment with immune suppression [7][8].
  • Speech Therapist: If you experience difficulty swallowing (dysphagia), a speech therapist can provide exercises to keep you safe from choking or lung infections [9].

The Medical Necessity of Sun Protection

For most people, “sun protection” is about preventing a sunburn. For someone with DM, it is a medical requirement. UV light (from the sun or even certain indoor lighting) does more than just damage the skin—it can trigger a systemic flare of the entire disease, including muscle weakness [10][11].

This happens because UV rays activate the Type I Interferon pathway, a central “on-switch” for inflammation in DM [12][13]. When UV light hits your skin cells, it can cause them to release inflammatory signals that travel through your bloodstream, potentially worsening symptoms throughout your body [10][14].

Strict UV protection includes:

  • Broad-spectrum sunscreen (SPF 50+) applied daily, even on cloudy days or when indoors near windows.
  • UPF 50+ sun-protective clothing, wide-brimmed hats, and UV-blocking window film for your car and home.
  • Avoiding peak sunlight hours (typically 10 AM to 4 PM).
  • Being aware of indoor lighting: Unshielded fluorescent or halogen bulbs can emit enough UV radiation to trigger skin flares. If your office or workplace uses these, you may need to wear sunscreen indoors or request LED bulb replacements.

Routine Monitoring in Remission

Even when you feel well, regular monitoring is necessary to ensure the disease stays quiet. Your “surveillance” schedule may include:

  1. Laboratory Tests: Routine blood work to monitor muscle enzymes like Creatine Kinase (CK) and AST, as well as inflammatory markers. Normalizing these labs is a key sign of disease control [15][16]. However, it is crucial to know that muscle enzymes can sometimes remain perfectly normal even during an active disease flare, especially in patients with CADM or anti-MDA5. Your physical stamina, skin symptoms, and how you feel are just as important as the numbers on your lab report.
  2. Lung Monitoring: Regular PFTs (especially FVC and DLCO) are used to track lung capacity. In some cases, a high-resolution CT (HRCT) scan may be repeated to check for stable lung tissue [17][18].
  3. Cancer Screening: Depending on your risk profile and antibody status (like anti-TIF1-γ\gamma), you may need annual screenings for several years [19][20].

Coping with ‘Scanxiety’

It is normal to feel significant stress or “scanxiety” before a scheduled test or while waiting for results [21][22]. This anxiety is a side effect of the monitoring process itself. To manage this, many patients find it helpful to [23][24]:

  • Request a specific date and time for when results will be discussed to avoid “waiting by the phone.”
  • Bring a support person to appointments.
  • Practice relaxation techniques or use virtual tools (like guided meditation) during the scan itself [25][26].
  • Communicate openly with your team about your anxiety—they can often adjust how results are delivered to help you feel more in control.

Frequently Asked Questions

Who should be on my dermatomyositis care team?
Your care team is typically led by a rheumatologist and should include a dermatologist for skin symptoms, a pulmonologist for lung health, and physical therapists for muscle strength. Depending on your specific symptoms, you may also need an oncologist or speech therapist.
Why is sun protection so important if I have dermatomyositis?
UV light from the sun or indoor lighting can trigger a systemic flare of your entire disease, not just a skin rash. It activates inflammatory pathways in your body that can worsen both skin symptoms and muscle weakness.
How often do I need blood tests when my dermatomyositis is in remission?
Routine blood work is necessary even in remission to monitor muscle enzymes and inflammatory markers. Your exact schedule will depend on your specific antibody profile and overall health, which your rheumatologist will determine.
What should I do if I experience anxiety before my medical scans?
It is very common to experience anxiety before medical tests. You can manage this by asking your doctor for a specific time to discuss results, bringing a support person to appointments, and practicing relaxation techniques during the scan.
Does a normal lab report mean my dermatomyositis is not flaring?
Normal muscle enzyme levels do not always mean your disease is fully controlled, especially if you have certain subtypes like CADM or anti-MDA5. Your doctor will also evaluate your physical stamina, skin symptoms, and how you feel overall.

Questions for Your Doctor

  • • Who is the 'lead' physician on my care team, and how will they coordinate information with my other specialists?
  • • Based on my antibody profile, what is my specific long-term schedule for blood work and cancer screenings?
  • • How often should I have pulmonary function tests (PFTs) even if I'm not currently experiencing shortness of breath?
  • • Are there specific sunscreens or types of UV-protective clothing you recommend for someone with my level of photosensitivity?
  • • What is the process for reviewing my scan results quickly so I can minimize 'scanxiety' while waiting?

Questions for You

  • • Does spending time in the sun or near a bright window seem to make your skin rash or muscle fatigue worse the next day?
  • • Do you have a support system or a counselor you can talk to about the stress of frequent medical monitoring?
  • • How are you currently tracking your lab results and appointments—would a digital app or a physical binder help you feel more organized?
  • • What lifestyle activities bring you the most joy, and how can we adapt them (like moving outdoor exercise to early morning) to keep you safe from UV rays?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy.

    Ahuja S, Makkar P, Gupta S, Vigoda I

    The Journal of community and supportive oncology 2016; (14(5)):229-31 doi:10.12788/jcso.0186.

    PMID: 27258056
  2. 2

    Management of Lung Manifestations in Idiopathic Inflammatory Myopathies.

    Krishnan A, Jain S, Lammi MR

    Rheumatic diseases clinics of North America 2025; (51(4)):623-641 doi:10.1016/j.rdc.2025.07.007.

    PMID: 41161904
  3. 3

    Clinical and Radiological Features of Interstitial Lung Diseases Associated with Polymyositis and Dermatomyositis.

    Palmucci S, Di Mari A, Cancemi G, et al.

    Medicina (Kaunas, Lithuania) 2022; (58(12)) doi:10.3390/medicina58121757.

    PMID: 36556960
  4. 4

    Anifrolumab Therapy in Dermatomyositis: New Insights From Refractory Patients.

    Carli L, Cavagna L, Cardelli C, et al.

    The Journal of rheumatology 2026; (53(2)):180-185 doi:10.3899/jrheum.2025-0773.

    PMID: 41176342
  5. 5

    The pathophysiological effects of exercise in the management of idiopathic inflammatory myopathies: A scoping review.

    Coskun Benlidayi I, Gupta L

    International journal of rheumatic diseases 2021; (24(7)):896-903 doi:10.1111/1756-185X.14104.

    PMID: 33793075
  6. 6

    Intravenous immunoglobulin is an effective steroid-sparing drug in inflammatory myositis.

    Nannarup A, Bartels LE, Næser EU

    Danish medical journal 2025; (72(12)) doi:10.61409/A02250076.

    PMID: 41312699
  7. 7

    Breast cancer and dermatomyositis: a case study and literature review.

    Hendren E, Vinik O, Faragalla H, Haq R

    Current oncology (Toronto, Ont.) 2017; (24(5)):e429-e433 doi:10.3747/co.24.3696.

    PMID: 29089813
  8. 8

    Severe Paraneoplastic Dermatomyositis in a Patient With High-Grade Serous Ovarian Cancer.

    Lajoie C, Brault C, Fortin S, et al.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2022; (44(6)):700-702 doi:10.1016/j.jogc.2022.01.015.

    PMID: 35691682
  9. 9

    Paraneoplastic Dermatomyositis presenting as Supraglottitis and acute heart failure; a case report.

    McCormick JP, Kenny A, Coyle M, et al.

    Oxford medical case reports 2025; (2025(9)):omaf167 doi:10.1093/omcr/omaf167.

    PMID: 41025033
  10. 10

    [Dermatomyositis-update].

    Volc-Platzer B

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2015; (66(8)):604-10 doi:10.1007/s00105-015-3659-0.

    PMID: 26219226
  11. 11

    Dermatomyositis autoantigen CHD4 forms immune stimulatory complexes with endogenous DNA.

    Guel T, Scholtissek B, Siegl J, et al.

    Experimental dermatology 2023; (32(7)):965-974 doi:10.1111/exd.14799.

    PMID: 36995066
  12. 12

    [Current update on dermatomyositis].

    Steininger J, Günther C

    Dermatologie (Heidelberg, Germany) 2024; (75(2)):153-162 doi:10.1007/s00105-023-05273-9.

    PMID: 38194097
  13. 13

    Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment.

    Ali H, On A, Xing E, et al.

    Seminars in immunopathology 2025; (47(1)):32 doi:10.1007/s00281-025-01054-9.

    PMID: 40770118
  14. 14

    The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent.

    Skopelja-Gardner S, An J, Tai J, et al.

    Scientific reports 2020; (10(1)):7908 doi:10.1038/s41598-020-64865-w.

    PMID: 32404939
  15. 15

    Imbalance of peripheral blood Th17/Treg increases neutrophil-to-lymphocyte ratio in patients with dermatomyositis.

    Zhang Z, Pang J, Li Y, et al.

    American journal of translational research 2023; (15(10)):6106-6114.

    PMID: 37969179
  16. 16

    Hepatitis B virus-related liver cirrhosis complicated with dermatomyositis: A case report.

    Zhang J, Wen XY, Gao RP

    World journal of clinical cases 2019; (7(10)):1206-1212 doi:10.12998/wjcc.v7.i10.1206.

    PMID: 31183354
  17. 17

    Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study.

    Mena-Vázquez N, Rojas-Gimenez M, Romero-Barco CM, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(10)) doi:10.3390/diagnostics11101794.

    PMID: 34679492
  18. 18

    Predictors of progression in systemic sclerosis patients with interstitial lung disease.

    Distler O, Assassi S, Cottin V, et al.

    The European respiratory journal 2020; (55(5)) doi:10.1183/13993003.02026-2019.

    PMID: 32079645
  19. 19

    International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative.

    Oldroyd AGS, Callen JP, Chinoy H, et al.

    Nature reviews. Rheumatology 2023; (19(12)):805-817 doi:10.1038/s41584-023-01045-w.

    PMID: 37945774
  20. 20

    Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives.

    Liu S, Zhang Z, Yan S, et al.

    Frontiers in oncology 2025; (15()):1503140 doi:10.3389/fonc.2025.1503140.

    PMID: 40535138
  21. 21

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  22. 22

    Scanxiety.

    Portman D

    Families, systems & health : the journal of collaborative family healthcare 2018; (36(3)):415 doi:10.1037/fsh0000353.

    PMID: 30198743
  23. 23

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  24. 24

    Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

    Hussain M, Chau S, Turner M, Paterson C

    Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

    PMID: 37735038
  25. 25

    VR-Based Anxiety Reduction Framework for Pediatric MRI Using Gamified Biofeedback.

    Roberts DM, Chen J, Martinez LK, et al.

    Research square 2025; doi:10.21203/rs.3.rs-7737172/v1.

    PMID: 41255995
  26. 26

    Effects of a 360° virtual counselling environment on patient anxiety and CCTA process time: A randomised controlled trial.

    Paalimäki-Paakki K, Virtanen M, Henner A, et al.

    Radiography (London, England : 1995) 2023; (29 Suppl 1()):S13-S23 doi:10.1016/j.radi.2022.09.013.

    PMID: 36280541

This page provides educational information about living with dermatomyositis. It is for informational purposes only and does not replace professional medical advice. Always consult your rheumatologist or care team about your specific management plan.

Stay up to date

Get notified when new research about Dermatomyositis is published.

No spam. Unsubscribe anytime.